Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2008 - 2011
  • Residency, Medicine, University of Washington 2005 - 2008
  • M.D., University of Chicago 2005
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2013
  • Instructor Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011
• Research
• 

  Selected Grants

  • Nektar awarded by Nektar Therapeutics 2018 - 2023
  • BP29541 awarded by F. Hoffmann-La Roche Ltd 2018 - 2023
  • AbbVie M14-064 awarded by AbbVie Inc. 2018 - 2023
  • AbbVie M16-438 awarded by AbbVie Inc. 2018 - 2023
  • Seattle Genetics-SGN2FF001: A Phase 1, multicenter, open-label, dose-escalation study awarded by Seattle Genetics, Inc 2017 - 2022
  • A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors. awarded by AbbVie Inc. 2016 - 2021
  • A Phase 3 Randomized double blined placebo controlled study to evaluate the efficacy and safety of GS-5745 conbimed with mFOLFAX6 as first line treatment in patients with advanced gastric or gastroeso awarded by Gilead Sciences, Inc. 2016 - 2021
  • Phase Ib study of Atezolizumab in combination with Bevacizumab in solid tumor patients awarded by Genentech, Inc. 2017 - 2021
  • A phase I open label dose escalation and dose-expansion study to evaluate the safety toloerability pharmcokinetics immunogenicity and antitumor activate of Medi-9447 alone and in combination with MEDI awarded by MedImmune, Inc. 2015 - 2020
  • A phase 1 first in human open labe dose escalation study of MGD007 a humanized gpA33 x CD3 dual affinity retargeted awarded by MacroGenics, Inc. 2014 - 2019
  • Mountaineer-Phase ll (ACCRU) awarded by Academic and Community Cancer Research United 2017 - 2019
  • A two part phase I multicenter ipen label study of DKN-01 in combination with weekly paclitaxel; Arm A; A dose awarded by Leap Therapeutics, Inc. 2014 - 2019
  • Cabozantinib (XL184) with panitumamab in KRAS wild-type metastatic colorectal cancer with pharmacodynamic studies, XL184 awarded by Exelixis, Inc 2014 - 2019
  • A Multicenter Phase I/Ib open label dose escalation study of ABBV-399, and antibody drug conjugate, in subjects with adv awarded by AbbVie Inc. 2014 - 2019
  • A randomized double blinded placebo controlled phase III study of adjuvant Regorafenib versus awarded by Bayer Healthcare Pharmaceuticals Inc 2013 - 2018
  • A Multicenter phase 1/1b open label dose escalation study of ABT-165 a dual variable domain immunoglobin in subject with awarded by AbbVie Inc. 2013 - 2018
  • A Phase ia/b dose escalation study of the safety pharmacokinetics and pharmacodynamics of OMP-131-R10 in advanced solid tumors and in combination awarded by OncoMed Pharmaceuticals 2016 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Conference Papers

    • Bekaii-Saab, T, Marcello, K, Fisher, G, Kopetz, S, Strickler, J, Venook, A, and Obholz, K. "Variability of current global practice patterns in the management of metastatic colorectal cancer." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Wainberg, Z, Strickler, J, Gordon, M, Barve, M, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Naumovski, L, and Hamilton, E. "Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Wainberg, Z, Wang, L, Yue, H, Motwani, M, Kasichayanula, S, Blaney, M, Naumovski, L, and Strickler, J. "ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress." ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, SPAIN. June 20, 2018 - June 23, 2018.: OXFORD UNIV PRESS, June 1, 2018.  Link to Item
    • Turner, M, Keenan, JE, Rushing, CN, Gulack, BC, Nussbaum, DP, Benrashid, E, Hyslop, T, Strickler, JH, Mantyh, CR, and Migaly, J. "ADJUVANT CHEMOTHERAPY IMPROVES SURVIVAL FOLLOWING RESECTION OF LOCALLY ADVANCED RECTAL CANCER WITH PATHOLOGIC COMPLETE RESPONSE." Annual Meeting of the American-Society-of-Colon-and-Rectal-Surgeon's. Nashville, TN. May 19, 2018 - May 23, 2018.: LIPPINCOTT WILLIAMS & WILKINS, May 1, 2018.  Link to Item
    • Berlin, J, Ramanathan, RK, Strickler, JH, Subramaniam, DS, Marshall, J, Kang, Y-K, Hetman, R, Dudley, MW, Zeng, J, Nickner, C, Xiong, H, Komarnitsky, P, Shepherd, SP, Hurwitz, H, and Lenz, H-J. "A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours." April 2018.  Full Text
    • Angevin, E, Strickler, J, Weekes, C, Heist, R, Morgensztern, D, Fan, X, Olyaie, O, Motwani, M, Afar, D, Naumovski, L, and Kelly, K. "First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)." January 2017.  Link to Item
    • Bendell, J, Eckhardt, GS, Hochster, HS, Morris, VK, Strickler, J, Kapoun, AM, Wang, M, Xu, L, McGuire, K, Dupont, J, Faoro, L, and Munster, P. "Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)." December 2016.  Full Text
    • Angevin, E, Kelly, K, Heist, R, Morgensztern, D, Weekes, C, Bauer, T, Ramanathan, R, Nemunaitis, J, Fan, X, Olyaie, O, Parikh, A, Reilly, E, Afar, D, Naumovski, L, and Strickler, J. "First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors." October 2016.  Full Text
    • Ryan, DP, Murphy, J, Mahalingam, D, Strickler, J, Stein, S, Sirard, C, Landau, S, and Bendell, J. "Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)." June 2016.  Link to Item
    • Clarke, JM, Blobe, GC, Strickler, JH, Uronis, HE, Zafar, Y, Morse, M, Dropkin, E, Howard, L, O'Neill, M, Rushing, CN, Niedzwiecki, D, Watson, H, Arrowood, C, and Hurwitz, H. "Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL)." May 20, 2016.  Full Text  Link to Item
    • Strickler, JH, Rushing, CN, Uronis, HE, Morse, M, Blobe, GC, Zafar, Y, Hsu, SD, Arrowood, C, Ley, SH, Dropkin, E, Niedzwiecki, D, and Hurwitz, H. "Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC)." May 20, 2016.  Full Text  Link to Item
    • Strickler, JH, Rangwala, FA, Rushing, C, Niedzwiecki, D, Altomare, I, Uronis, HE, Hsu, SD, Zafar, Y, Morse, M, Chang, DZ, Wells, JL, Blackwell, KL, Marcom, PK, Webb, AR, Dropkin, E, Arrowood, C, and Hurwitz, H. "X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC)." February 2016.  Full Text
    • Zhang, T, Boominathan, R, Foulk, B, Connelly, MC, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, George, DJ, Hurwitz, H, Garcia-Blanco, MA, and Armstrong, AJ. "Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies." May 20, 2015.  Link to Item
    • Kang, Y-K, LoRusso, P, Salgia, R, Yen, C-J, Lin, C-C, Ramanathan, RK, Kaminker, P, Sokolova, I, Bhathena, A, Wang, L, Naumovski, L, and Strickler, JH. "Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC)." January 20, 2015.  Full Text
    • O'Reilly, EM, Smith, LS, Bendell, JC, Strickler, JH, Zalupski, M, Gluck, W, Kapoun, A, Yen, W-C, Xu, L, Hill, D, Zhou, L, Dupont, J, and Cohn, AL. "Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)." January 20, 2015.  Full Text
    • Kapoun, A, O'Reilly, E, Cohn, A, Bendell, J, Smith, L, Strickler, J, Gluck, W, Liu, Y, Wallace, B, Tam, R, Cancilla, B, Brunner, A, Hill, D, Zhou, L, Dupont, J, Zhang, C, and Wang, M. "465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)." November 2014.  Full Text
    • Strickler, JH, LoRusso, P, Yen, C-J, Lin, C-C, Kang, Y-K, Kaminker, P, Ansell, P, Bhathena, A, Wong, S, Dudley, MW, Naumovski, L, and Ramanathan, RK. "Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors." May 20, 2014.  Link to Item
    • Strickler, JH, McCall, S, Nixon, AB, Pang, H, Rushing, C, Arrowood, C, Haley, S, Meadows, K, and Hurwitz, H. "Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors." May 20, 2013.  Link to Item
    • Hurwitz, H, Pitot, H, Strickler, J, Sorensen, JM, Leopold, L, Brill, J, and Smith, DC. "Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas." November 2012.  Full Text  Link to Item
    • Kollmannsberger, CK, Hurwitz, H, Cleary, JM, Strickler, JH, Drouin, MA, Juretic, M, Hunt, W, Reid, GK, Maroun, CR, Bonfils, C, Wang, J, Karam, A, Besterman, JM, Mehran, M, and Shapiro, G. "MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study." May 20, 2012.  Link to Item

  • Journal Articles

    • Graham, CN, Christodoulopoulou, A, Knox, HN, Sabatelli, L, Hechmati, G, Garawin, T, and Strickler, JH. "A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US." Journal of Medical Economics 21, no. 11 (November 2018): 1075-1083.  Full Text
    • Strickler, JH, Weekes, CD, Nemunaitis, J, Ramanathan, RK, Heist, RS, Morgensztern, D, Angevin, E, Bauer, TM, Yue, H, Motwani, M, Parikh, A, Reilly, EB, Afar, D, Naumovski, L, and Kelly, K. "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology (October 4, 2018): JCO2018787697-null.  Full Text
    • Strickler, JH. "EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?." Cancer Discovery 8, no. 6 (June 2018): 679-681.  Full Text
    • Strickler, JH, Loree, JM, Ahronian, LG, Parikh, AR, Niedzwiecki, D, Pereira, AAL, McKinney, M, Korn, WM, Atreya, CE, Banks, KC, Nagy, RJ, Meric-Bernstam, F, Lanman, RB, Talasaz, A, Tsigelny, IF, Corcoran, RB, and Kopetz, S. "Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer." Cancer Discovery 8, no. 2 (February 2018): 164-173.  Full Text
    • Jia, J, Morse, MA, Nagy, RJ, Lanman, RB, and Strickler, JH. "Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer." Frontiers in Oncology 8 (January 2018): 305-null.  Full Text
    • Tachibana, M, Papadopoulos, KP, Strickler, JH, Puzanov, I, Gajee, R, Wang, Y, and Zahir, H. "Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours." British Journal of Clinical Pharmacology 84, no. 1 (January 2018): 112-121.  Full Text
    • Strickler, JH, Wu, C, and Bekaii-Saab, T. "Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches." Cancer Treatment Reviews 60 (November 2017): 109-119. (Review)  Full Text
    • Zhu, J, and Strickler, JH. "Clinical applications of liquid biopsies in gastrointestinal oncology." Journal of gastrointestinal oncology 7, no. 5 (October 2016): 675-686. (Review)  Full Text  Open Access Copy
    • Balaban, EP, Mangu, PB, Khorana, AA, Shah, MA, Mukherjee, S, Crane, CH, Javle, MM, Eads, JR, Allen, P, Ko, AH, Engebretson, A, Herman, JM, Strickler, JH, Benson, AB, Urba, S, and Yee, NS. "Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 22 (August 2016): 2654-2668.  Full Text
    • Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Mol Cancer Res 14, no. 6 (June 2016): 539-547.  Full Text  Open Access Copy  Link to Item
    • Roe, MT, Cyr, DD, Eckart, D, Schulte, PJ, Morse, MA, Blackwell, KL, Ready, NE, Zafar, SY, Beaven, AW, Strickler, JH, Onken, JE, Winters, KJ, Houterloot, L, Zamoryakhin, D, Wiviott, SD, White, HD, Prabhakaran, D, Fox, KAA, Armstrong, PW, Ohman, EM, and TRILOGY ACS Investigators, . "Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." European Heart Journal 37, no. 4 (January 2016): 412-422.  Full Text
    • Zhu, J, Strosberg, JR, Dropkin, E, and Strickler, JH. "Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX." Journal of Gastrointestinal Cancer 46, no. 2 (June 2015): 166-169.  Full Text
    • Hurwitz, HI, Smith, DC, Pitot, HC, Brill, JM, Chugh, R, Rouits, E, Rubin, J, Strickler, J, Vuagniaux, G, Sorensen, JM, and Zanna, C. "Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study." Cancer chemotherapy and pharmacology 75, no. 4 (April 2015): 851-859.  Full Text
    • Hurwitz, HI, Smith, DC, Pitot, HC, Brill, JM, Chugh, R, Rouits, E, Rubin, J, Strickler, J, Vuagniaux, G, Sorensen, JM, and Zanna, C. "Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study." Cancer Chemotherapy and Pharmacology 75, no. 4 (January 1, 2015): 851-859.  Full Text
    • Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational new drugs 32, no. 4 (August 2014): 700-709.  Full Text
    • Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Invest New Drugs 32, no. 2 (April 2014): 330-339.  Full Text  Link to Item
    • Nussbaum, DP, Bhattacharya, SD, Jiang, X, Cardona, DM, Strickler, JH, and Blazer, DG. "Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplication." Archives of pathology & laboratory medicine 138, no. 3 (March 2014): 428-431.  Full Text
    • Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational New Drugs 32, no. 4 (January 1, 2014): 700-709.  Full Text
    • Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase i study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Investigational New Drugs 32, no. 2 (January 1, 2014): 330-339.  Full Text
    • Strickler, JH, and Hurwitz, HI. "Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?." Current Oncology Reports 16, no. 1 (2014): 1-8.
    • Strickler, JH, and Hurwitz, HI. "Palliative treatment of metastatic colorectal cancer: what is the optimal approach?." Curr Oncol Rep 16, no. 1 (2014): 363-. (Review)  Full Text  Link to Item
    • Strickler, JH, and Hurwitz, HI. "Palliative treatment of metastatic colorectal cancer: What is the optimal approach? Topical collection on gastrointestinal cancers." Current Oncology Reports 16, no. 1 (January 1, 2014).  Full Text
    • Strickler, JH, and Hurwitz, HI. "Palliative treatment of metastatic colorectal cancer: what is the optimal approach?." Current oncology reports 16, no. 1 (2014): 363--.  Full Text
    • Tachibana, M, Papadopoulos, KP, Strickler, J, Puzanov, I, Gajee, R, Wang, Y, and Zahir, H. "Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach." Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C85-C85.  Full Text
    • Roe, MT, Armstrong, PW, Fox, KAA, White, HD, Prabhakaran, D, Goodman, SG, Cornel, JH, Bhatt, DL, Clemmensen, P, Martinez, F, Ardissino, D, Nicolau, JC, Boden, WE, Gurbel, PA, Ruzyllo, W, Dalby, AJ, McGuire, DK, Leiva-Pons, JL, Parkhomenko, A, Gottlieb, S, Topacio, GO, Hamm, C, Pavlides, G, Goudev, AR, Oto, A, Tseng, C-D, Merkely, B, Gasparovic, V, Corbalan, R, Cinteză, M, McLendon, RC, Winters, KJ, Brown, EB, Lokhnygina, Y, Aylward, PE, Huber, K, Hochman, JS, Ohman, EM, and TRILOGY ACS Investigators, . "Prasugrel versus clopidogrel for acute coronary syndromes without revascularization." The New England Journal of Medicine 367, no. 14 (October 2012): 1297-1309.  Full Text
    • Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251-258.  Full Text  Link to Item
    • Strickler, JH, and Hurwitz, HI. "Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability." The Oncologist 17, no. 1 (January 10, 2012): 9-10.  Full Text
    • Strickler, JH, and Hurwitz, HI. "Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer." The Oncologist 17, no. 4 (January 2012): 513-524. (Review)  Full Text
    • Strickler, JH, Cohn, AL, Arrowood, C, Haley, S, Morse, M, Uronis, H, Blobe, GC, Hsu, SD, Zafar, Y, and Hurwitz, H. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 3586-3586.  Full Text
    • Strickler, JH, Cohn, AL, Arrowood, C, Haley, S, Morse, M, Uronis, H, Blobe, GC, Hsu, SD, Zafar, Y, and Hurwitz, H. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 3586-.
    • Kline, J, Brown, IE, Zha, Y-Y, Blank, C, Strickler, J, Wouters, H, Zhang, L, and Gajewski, TF. "Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma." Clinical Cancer Research 14, no. 10 (2008): 3156-3167.  Full Text
    • Coil, DA, Strickler, JH, Rai, SK, and Miller, AD. "Jaagsiekte Sheep Retrovirus Env Protein Stabilizes Retrovirus Vectors against Inactivation by Lung Surfactant, Centrifugation, and Freeze-Thaw Cycling." Journal of Virology 75, no. 18 (September 15, 2001): 8864-8867.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.